500 related articles for article (PubMed ID: 37610978)
1. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.
Koning M; Herrema H; Nieuwdorp M; Meijnikman AS
Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
3. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
4. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
5. Promises of microbiome-based therapies.
Bajaj JS; Ng SC; Schnabl B
J Hepatol; 2022 Jun; 76(6):1379-1391. PubMed ID: 35589257
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome and non-alcoholic fatty liver disease.
Purohit A; Alam MJ; Kandiyal B; Shalimar ; Das B; Banerjee SK
Prog Mol Biol Transl Sci; 2022; 191(1):187-206. PubMed ID: 36270678
[TBL] [Abstract][Full Text] [Related]
8. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
9. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
Ma J; Zhou Q; Li H
Nutrients; 2017 Oct; 9(10):. PubMed ID: 29035308
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
[TBL] [Abstract][Full Text] [Related]
11. The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis.
Amini-Salehi E; Hassanipour S; Keivanlou MH; Shahdkar M; Orang Goorabzarmakhi M; Vakilpour A; Joukar F; Hashemi M; Sattari N; Javid M; Mansour-Ghanaei F
Nutr Rev; 2024 May; 82(6):815-830. PubMed ID: 37550264
[TBL] [Abstract][Full Text] [Related]
12. Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease.
Mijangos-Trejo A; Nuño-Lambarri N; Barbero-Becerra V; Uribe-Esquivel M; Vidal-Cevallos P; Chávez-Tapia N
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834367
[TBL] [Abstract][Full Text] [Related]
13. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
15. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
Huang W; Kong D
Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
[TBL] [Abstract][Full Text] [Related]
16. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Safari Z; Gérard P
Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
[TBL] [Abstract][Full Text] [Related]
17. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.
Hartmann P; Schnabl B
Semin Liver Dis; 2021 Jan; 41(1):87-102. PubMed ID: 33957682
[TBL] [Abstract][Full Text] [Related]
18. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
19. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]